Ex vivo gene therapy in the treatment of Parkinson's disease;Terapia génica ex vivo en el tratamiento de la enfermedad de Parkinson

Revista de Neurologia

Volumn 36, Issue 11, 2003, Pages 1073-1077

  García Miniet, Rocio ^a   Alberti Amador, E ^a   Castellano Ortega, M R ^a  

^a CENTRO INTERNACIONAL DE RESTAURACIÓN NEUROLÓGICA CIREN   (Cuba)

Author keywords

AADC; GDNF; Gene therapy; GTP cyclohydrolase I; Parkinson's disease; TH; Viral vectors

Indexed keywords

AROMATIC LEVO AMINO ACID DECARBOXYLASE; DOPAMINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLIAL CELL-LINE DERIVED NEUROTROPHIC FACTOR; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; NERVE GROWTH FACTOR; NEUROTROPHIC FACTOR; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; VIRUS VECTOR;

BIOSYNTHESIS; CELL DIFFERENTIATION; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM; DEGENERATIVE DISEASE; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; ENZYMOLOGY; GENE THERAPY; GENETICS; HUMAN; IMPLANTATION; METABOLISM; NERVE DEGENERATION; PARKINSON DISEASE; PATHOPHYSIOLOGY; REVIEW;

EID: 0042306139     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3611.2002262     Document Type: Review

References (30)

1. Bohn M. Parkinson's disease: a neurodegenerative disease particularly amenable to gene therapy. Mol Ther 2001; 1: 494-6.
2. Poduslo JF, Curran GL. Permeability at the blood-brain and blood-nerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF. Mol Brain Res 1996; 36: 280-6.
3. Bensadoun JC, Déglon N, Tseng JL, Ridet JL, Zurn AD, Aebischer P. Lentiviral vectors as a gene delivery system in the mouse midbrain: cellular and behavioural improvements in a 6-OHDA model of Parkinson's disease using GDNF. Exp Neurol 2000; 164: 15-24.
4. Renfranz PJ, Cunningham MG, McKay DG. Region-specific differentiation of the hippocampal stem cell line HiB5 upon implantation into the developing mammalian brain. Cell 1991; 66: 713-29.
5. Hoshimaru M, Ray J, Sah D, Gage FH. Differentiation of the immortalized adult neuronal progenitor cell line HC2S2 into neurons by regulatable suppression of the v-myc oncogen. Proc Natl Acad Sci 1996; 93: 1518-23.
6. Freese A, Stern M, Kaplitt MG, O'Connor WM, Abbey MV, O'Connor MJ, et al. Prospects for gene therapy in Parkinson's disease. Mov Disord 1996; 11: 469-88.
7. Baekelandt V, De Strooper B, Nuttin B, Debyser Z. Gene therapeutic strategies for neurodegenerative diseases. Curr Opin Mol Ther 2000; 2: 540-54.
8. Kang UJ. Potencial of gene therapy for Parkinson's disease: neurobiologic issues and new developments in gene transfer methodologies. Mov Disord 1998; 13 (Suppl 1): 59-72.
9. Bencsics C, Wachtel SR, Milstien S, Hatakeyama K, Becker JB, Kang UJ. Double transduction with GTP cyclohydrolase I and Tyrosine hydroxylase is necessary for spontaneous synthesis of L-Dopa by primary fibroblasts. J Neurosci 1996; 16: 4449-56.
10. Snyder EY, Wolf JH. Central nervous system cell transplantation: a novel therapy for storage diseases? Curr Opin Neurol 1996; 9: 126-36.
11. Cortez N, Trejo F, Vergara P, Segovia J. Primary astrocytes retrovirally transduced with a tyrosine hydroxylase transgene driven by a glial-specific promoter elicit behavioural recovery in experimental parkisonism. J Neurosci Res 2000; 59: 39-46.
12. Segovia J, Vergara P, Brenner M. Astrocyte-specific expresion of tyrosine hydroxylase after intracerebral gene transfer induces behavioural recovery in experimental parkisonism. Gene Ther 1998; 5: 1650-5.
13. National Institute of Health. Stem cells: scientific progress and futur research directions. Rebuilding the nervous system with stem cells. National Institute of Health; 2001. p. 77-85.
14. Leone P, McPhee WJ, Janson CG, Davidson BL, Freese A, During MJ. Multi-site partitioned delivery of human tyrosine hydroxylase gene with phenotypic recovery in Parkinsonian rats. Neuroreport 2000; 11: 1145-51.
15. Kozlowski DA, Bremer E, Redmond DE, George D, Larson B, Bohn M. Quantitative analisis of transgene protein, mRNA, and vector DNA following injection of an adenoviral vector harbouring glial cell line-derived neurotrophic factor into the primate caudate nucleus. Mol Ther 2000; 3: 256-61.
16. Shen Y, Muramatsu SI, Ikeguchi K, Fujimoto KI, Fan DS, Ogawa M, et al. Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease. Hum Gene Ther 2000; 11: 1509-19.
17. Kirik D, Rosenblad C, Björklund A, Mandel RJ. Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J Neurosci 2000; 20: 4686-700.
18. During MJ, Naegele JR, O'Malley KL, Geller AI. Long-term behavioural recovery in parkinsonian rats by an HSV vector expressing tyrosine hydroxylase. Science 1994; 266: 1399-403.
19. Kordower JH, Emborg ME, Bloch J, Ma SY, Chu Y, Leventhal L, et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primates models of Parkinson's disease. Science 2000; 290: 661-888.
20. Hideki H, Hashimoto M, Fujimoto I, Nakajima K, Shimano Y, Nagatsu T, et al. Dopa-producing astrocytes generated by adenoviral transduction of human tyrosine hydroxilase gene: in vitro study and transplantation to hemaparkinsonian model rats. Neurosci Res 1999; 35: 101-12.
21. Tacconi MT. Neuronal death: is there a role for astrocytes? Neurochem Res 1998; 23: 759-65.
22. Segovia J, Vergara P, Brenner M. Differentiation-dependent expression of transgenes in engineered astrocyte cell lines. Neurosci Lett 1998; 242: 172-6.
23. Mandel RJ, Rendahl KG, Spratt SK, Snyder RO, Cohen LK, Leff SE. Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase I in a rat model of Parkinson's disease. J Neurosci 1998; 18: 4271-84.
24. Leff SE, Rendahl KG, Spratt SK, Kang UJ, Mandel RJ. In vivo LDOPA production by genetically modified primary rat fibroblast or gliosarcoma cell grafts via coexpression of GTP cyclohydrolase I with tyrosine hydroxylase. Exp Neurol 1998; 151: 249-64.
25. Ziiu MY, Jourio AV. Aromatic L-amino acid decarboxilase: biological characterization and functional role. Gen Pharmacol 1995; 26: 681-96.
26. Fan DS, Ogawa M, Fujimoto KI, Ikeguchi K, Ogasawara Y, Urabe M, et al. Behavioral recovery in 6-OHDA-lesioned rats by cotransduction of striatum with tyrosine hydroxylase and aromatic L-amino acid decarboxylase genes using two separate adeno-associated virus vector. Hum Gene Ther 1998; 9: 2527-35.
27. Bankiewicz KS, Eberling JL, Kohutnicka M, Jagust W, Pivirotto P, Bringas J, et al. Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp Neurol 2000; 164: 2-14.
28. Bilang-Bleuel A, Revah F, Colin P, Locquet I, Robert JJ, Mallet J, et al. Intrastriatal injection of adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioural impairment in rat model of Parkinson disease. Proc Natl Acad Sci 1997; 94: 8818-23.
29. Park KW, Eglitis MA, Mouradian M. Protection of nigral neurons by GDNF-engineered marrow cell transplantation. Neurosci Res 2001; 40: 315-23.
30. Nakao N, Yokote H, Nakai K, Itakura T. Promotion of survival and regeneration of nigral dopamine neurons in a rat model of Parkinson's disease after implantation of embryonal carcinoma-derived neurons genetically engineered to produce glial cell line-derived neurotrophic factor. J Neurosurg 2000; 92: 659-70.